Can AAV be used in vitro?

Can AAV be used in vitro?

AAVs have been used to express transgenes in vivo, but in vitro applications are rare. However, as we show here using primary mouse hepatocytes and skeletal muscle-derived C2C12 cells, AAV2-DJ efficiently infects cells in vitro.

How are viral capsids made?

Nascent capsids are filled with viral DNA (through the portal complex) in a process that requires energy. DNA is packaged in a “headful” mechanism whereby concatemers are cleaved at conserved sequences that define the genome ends. The DNA is tightly packed, producing a rigid capsid and the capsid is “sealed” by a PCP.

What are the 2 major viral capsid types?

There are two major classes of viruses based on the protein capsid: (1) those in which a single (or segmented) linear nucleic acid molecule with two free ends is essentially completely extended or somewhat coiled (a helix) and (2) those in which the nucleic acid, which may or may not be a covalently closed circle, is …

What are AAV capsids?

The protein shell (capsid) of Adeno-associated viruses (AAV) are presently the most promising delivery vehicles for various in vivo gene therapies. AAVs are non-pathogenic and, through past engineering efforts, have become safe due to their inability to integrate into and damage the genome of target cells.

How do adeno-associated viruses work?

How does AAV work? Simply put, AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced.

What are viral capsids composed of?

The capsid surrounds the virus and is composed of a finite number of protein subunits known as capsomeres, which usually associate with, or are found close to, the virion nucleic acid.

Which technique is used to study structure of capsid?

With fluorescence correlation spectroscopy (FCS), important insights into studies of virus capsids and their assembly reaction in vitro have been made.

What are capsids composed of?

Which viruses have a helical capsid?

In contrast, all helical animal viruses are enveloped. These include well-known viruses such as influenza virus, measles virus, mumps virus, rabies virus, and Ebola virus (Fig. 2.5 ). Electron micrographs of helical viruses.

What type of virus is AAV?

Adeno-associated viruses (AAV) are small viruses that infect humans and some other primate species. They belong to the genus Dependoparvovirus, which in turn belongs to the family Parvoviridae.

What is the AAV capsid made of?

viral proteins
AAV capsids consist of a total of 60 molecules of viral proteins (VPs); a mixture of the three overlapping gene products, VP1, VP2, and VP3, encoded by the cap open reading frame (ORF) and organized in T = 1 icosahedral symmetry (Fig. 1)19.

What is the adeno-associated virus (AAV) capsid structure?

Fig. 1: Adeno-associated virus (AAV) capsid structure. a The capsid is composed of 60 copies of a combination of VP1, VP2, and VP3. For the VPs we use the green, red, and gray color scheme, respectively, throughout the manuscript.

What is the function of VP3 in capsid assembly?

VP3 is the main structural protein and can form VP3-only capsids 8. The right ORF cassette also codes in a different reading frame for the assembly-activating protein (AAP), which promotes capsid assembly by increasing capsid protein stability and VP-VP interactions 9, 10.

Does Assembly-Activating Protein (AAP) increase capsid yield in VLPs?

VLPs developed without assembly-activating protein (AAP), but adding purified recombinant AAP to the refolding process increased capsid yield.

Can AAV empty capsids produced in HEK-293 cells be modified for vaccination?

Previous studies showed that AAV empty capsids produced in HEK-293 cells can be modified to present epitopes for vaccination 16, 17. Moreover, the concept of AAV VLP production using a yeast expression system was introduced 18. AAV vectors have had increasing successes in recent clinical gene therapy trials.

author

Back to Top